Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT06494111
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
295 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Lymphedema


Fibrosis
ACTIVE_NOT_RECRUITING
NCT06429761
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
100 Enrollment(s)
7 Study location(s)
INTERVENTIONAL (PHASE4)
BREAST CANCER
RECRUITING
NCT05845450
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
197 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Colorectal Cancer


Resectable Colorectal Carcinoma
RECRUITING
NCT05573893
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
800 Enrollment(s)
109 Study location(s)
OBSERVATIONAL (None)
Breast Neoplasms


Breast Cancer


Neoplasm Metastasis
RECRUITING
NCT04616560
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
55 Enrollment(s)
29 Study location(s)
INTERVENTIONAL (PHASE2)
Desmoplastic Small Round Cell Tumor


Osteosarcoma


Recurrent Desmoplastic Small Round Cell Tumor


Recurrent Kidney Wilms Tumor


Recurrent Osteosarcoma


Refractory Desmoplastic Small Round Cell Tumor


Refractory Wilms Tumor


Wilms Tumor
COMPLETED
NCT04471870
ARCANGELO (itAlian pRospective Study on CANGrELOr)
1,005 Enrollment(s)
30 Study location(s)
OBSERVATIONAL (None)
Acute Coronary Syndrome
RECRUITING
NCT03424005
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
1,132 Enrollment(s)
53 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer
RECRUITING
NCT07810088
Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer
40 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
HR+ / HER2- Advanced Breast Cancer